{
    "clinical_study": {
        "@rank": "109122", 
        "acronym": "CEASE-MS", 
        "arm_group": {
            "arm_group_label": "RHB-104", 
            "arm_group_type": "Experimental", 
            "description": "5 RHB-104 capsules administered orally BID"
        }, 
        "brief_summary": {
            "textblock": "The investigators hypothesize that Mycobacterium avium paratuberculosis positive Relapsing\n      Remitting MS subjects will have a greater response to Interferon beta-1a therapy plus\n      RHB-104 than from Interferon beta-1a alone."
        }, 
        "brief_title": "Proof of Concept Study of RHB-104 as Add-On Therapy to Interferon Beta-1a in Relapsing Remitting Multiple Sclerosis (RRMS)", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Relapsing Remitting Multiple Sclerosis", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Sclerosis", 
                "Sclerosis", 
                "Multiple Sclerosis, Relapsing-Remitting"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males and females aged \u226518 years\n\n          -  Signed fully informed consent provided as per this protocol and willing to comply\n             with the required scheduled assessments of the protocol.\n\n          -  Diagnosis of relapsing-remitting multiple sclerosis (McDonald Criteria (2010)) with\n             dissemination in time and space.\n\n          -  Currently treated with a stable dose of Rebif\u00ae, or Avonex\u00ae for a minimum of 3 months\n             duration prior to the screening visit.\n\n          -  Active MS with history of at least one flare within the past 12 months or two flares\n             in the past 24 months prior to screening.\n\n          -  An Expanded Disability Status Scale (EDSS) of 6.0 or less at the screening visit.\n\n          -  White blood cell count \u2265 3.5x109.\n\n        Exclusion Criteria:\n\n          -  Treatment with any other biological therapies including but not limited to Interferon\n             beta-1b, natalizumab, anti-tumor necrosis factor (anti-TNF) biologic agents, or other\n             agents intended to reduce TNF \u2264 8 weeks prior to screening or within 5 half-lives of\n             agent prior to screening, whichever is longer.\n\n          -  Previous treatment with rifabutin and/or clofazimine.\n\n          -  Oral or parenteral antibiotics in the 4 weeks prior to screening. (Topical\n             antibiotics are permitted.)\n\n          -  Use of Methylprednisolone sodium succinate, prednisone, or any other corticosteroid\n             during the 30 days prior to screening.\n\n          -  Relapse within 30 days before screening.\n\n          -  Initiation or dose modification of 4-aminopyridine within 60 days of screening.\n\n          -  Use of azathioprine, 6-mercaptopurine (6-MP), methotrexate, cyclosporine or\n             mycophenolate (CellCept) within 8 weeks prior to screening.\n\n          -  Use of glatiramer acetate, cyclophosphamide, or plasma exchange within 12 weeks prior\n             to screening.\n\n          -  Use of mitoxantrone within one year prior to screening.\n\n          -  Any previous treatment with cladribine, T cell vaccine, or altered peptide ligand.\n\n          -  Previous total body irradiation or total lymphoid irradiation.\n\n          -  Treatment with any medication that has the potential to prolong QT interval or cause\n             Torsades de Pointes within 7 days of screening, including: Cisapride,\n             pimozide,astemizole, terfenadine, ergotamine, dihydroergotamine, quinidine,\n             procainamide, disopyramide, amiodarone, sotalol, ibutilde, dofetilide and\n             dronedarone.\n\n          -  Treatment with any medication that is a CYP3A4 substrate, including: colchicine,\n             simvastatin, lovastatin, atorvastatin, verapamil, amlodipine, diltiazem, sildenafil,\n             tadalafil, vardenafil, fluconazole and midazolam.\n\n          -  Treatment with any contraindicated medications as listed in the prescriber\n             information for each respective antibiotic found in RHB-104. (See Investigator\n             Brochure (IB))\n\n          -  Serious adverse reaction or hypersensitivity to the study drug or any medications\n             related to the study drug.\n\n          -  Clinically significant abnormalities of hematology or biochemistry, including but not\n             limited to, elevations greater than 2 times the upper limit of normal of Aspartate\n             Aminotransferase (AST), Alanine Aminotransferase (ALT), Alkaline Phosphatase or\n             creatinine clearance less than 60 ml/min at screening.\n\n          -  Serum potassium, magnesium or calcium outside the normal reference range.\n\n          -  Positive stool results for C. difficile.\n\n          -  A positive serology for Hepatitis B, Hepatitis C or HIV at screening.\n\n          -  History of the following diseases:\n\n               -  Atypical mycobacterial infections (other than MAP)\n\n               -  Active tuberculosis requiring treatment in the past 3 years\n\n               -  Positive quantiFERON test\n\n          -  Currently diagnosed or history of uveitis confirmed by either an ophthalmologist or\n             optometrist.\n\n          -  Any evidence of any other significant hematological, hepatic, renal, cardiac,\n             pulmonary, metabolic, thyroid, neurological or psychiatric disease that might\n             interfere with the subject's ability to safely enter and or complete the study\n             requirements.\n\n          -  Males who do not use barrier contraceptive methods (i.e. condom) with spermicidal\n             foam/gel/cream/suppository or have not had a vasectomy.\n\n          -  Females who are not post-menopausal for at least the previous 12 months, have not had\n             a hysterectomy or tubal ligation or females of child bearing potential who:\n\n               1. have a positive pregnancy test\n\n               2. are lactating\n\n               3. have not used oral contraceptives for at least three continuous months prior to\n                  date of screening\n\n               4. do not use nonhormonal contraceptive methods such as barrier (i.e. diaphragm,\n                  cervical cap, and contraceptive sponge) with spermicidal\n                  foam/gel/cream/suppository, or intrauterine device (IUD) unless their partner(s)\n                  use barrier contraceptive methods with spermicidal foam/gel/cream/suppository or\n                  have had a vasectomy\n\n          -  Refusal to sign the study informed consent form.\n\n          -  Inability to adequately communicate with the investigator or their respective\n             designee and/or comply with the requirements of the entire study.\n\n          -  History of drug or alcohol abuse.\n\n          -  Participation in any experimental drug protocol within 12 weeks of date of screening.\n\n          -  Cardiac pacemaker or any other type of metal implant or any other contraindication\n             for MRI (including known allergy to gadolinium).\n\n          -  Corrected QT interval (QTc)>440ms, bundle branch block, or major T wave abnormalities\n             that make the assessment of the QT impossible.\n\n          -  History of unstable cardiac syndromes including unstable angina, coronary artery\n             bypass graft, myocardial infarction or coronary stenting within 2 months; New York\n             Heart Association Class 3-4 congestive heart failure; history of ventricular\n             tachycardia, ventricular fibrillation, personal or family history of sudden death,\n             Long QT Syndrome, or Torsade de Pointes; heart rate <50 beats per minute; taking any\n             Class 1 or Class 3 antiarrhythmic medications or medicines known to prolong the QT\n             interval or be associated with Torsade de Pointes."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "16", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 24, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01717664", 
            "org_study_id": "RHB-104-02"
        }, 
        "intervention": {
            "arm_group_label": "RHB-104", 
            "description": "95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine", 
            "intervention_name": "RHB-104", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Interferon-beta", 
                "Interferons", 
                "Interferon beta 1a"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Relapsing Remitting Multiple Sclerosis", 
            "MAP", 
            "antibiotic", 
            "Interferon beta 1-a", 
            "MS", 
            "MRI", 
            "EDSS", 
            "relapse rate"
        ], 
        "lastchanged_date": "February 20, 2014", 
        "location": [
            {
                "contact": {
                    "email": "orenw@tlvmc.gov.il", 
                    "last_name": "Oren Weintraub"
                }, 
                "facility": {
                    "address": {
                        "city": "Tel Aviv", 
                        "country": "Israel"
                    }, 
                    "name": "RedHill MS Clinical Trial Site 002"
                }, 
                "investigator": {
                    "last_name": "Arnon Karni", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "wadad.n@ziv.health.gov.il", 
                    "last_name": "Wedad Nachle"
                }, 
                "facility": {
                    "address": {
                        "city": "Zefat (Safed)", 
                        "country": "Israel"
                    }, 
                    "name": "RedHill MS Clinical Trials Site 001"
                }, 
                "investigator": {
                    "last_name": "Radi Shahien, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase IIa Proof of Concept Study to Assess the Efficacy and Safety of Fixed Dose Combination RHB-104 as Add-On Therapy to Interferon Beta-1a in Patients Treated for Relapsing Remitting Multiple Sclerosis", 
        "other_outcome": [
            {
                "measure": "Combined Unique Active lesions", 
                "safety_issue": "No", 
                "time_frame": "Week 24  to Week 48"
            }, 
            {
                "measure": "Change in cytokine panel", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 24"
            }, 
            {
                "measure": "Change in cytokine panel", 
                "safety_issue": "No", 
                "time_frame": "Week 24 to Week 48"
            }, 
            {
                "measure": "MAP status as established by polymerase chain reaction (PCR)", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 24"
            }, 
            {
                "measure": "MAP status as established by polymerase chain reaction (PCR)", 
                "safety_issue": "No", 
                "time_frame": "Week 24 to Week 48"
            }, 
            {
                "measure": "Relapses", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 24"
            }, 
            {
                "measure": "Relapses", 
                "safety_issue": "No", 
                "time_frame": "Week 24 to Week 48"
            }, 
            {
                "measure": "Expanded Disability Status Scale (EDSS)", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 24"
            }, 
            {
                "measure": "Expanded Disability Status Scale (EDSS)", 
                "safety_issue": "No", 
                "time_frame": "Week 24 to Week 48"
            }, 
            {
                "measure": "Number of participants with adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline through Week 24"
            }
        ], 
        "overall_contact": {
            "email": "info@redhillbio.com", 
            "last_name": "RedHill Biopharma", 
            "phone": "+972-(0)3-541-3131"
        }, 
        "overall_contact_backup": {
            "email": "ira@redhillbio.com", 
            "last_name": "Ira N Kalfus, MD", 
            "phone": "+1-917-817-7517"
        }, 
        "overall_official": [
            {
                "affiliation": "RedHill Biopharma", 
                "last_name": "Ira N Kalfus, MD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Ziv Medical Center", 
                "last_name": "Radi Shahien, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Israel: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Combined Unique Active lesions", 
            "safety_issue": "No", 
            "time_frame": "Baseline through Wk 24"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01717664"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "RedHill Biopharma Limited", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "RedHill Biopharma Limited", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}